Prohibition of GSK dual pricing in Spain (2001)

European Commission decision (about 36 pages) prohibiting under Article 81 contracts between the pharmaceutical manufacturer GSK and its Spanish distributors which set different prices depending on whether drugs were to be used within the Spanish health service. The Commission found that the contracts restricted competition by making parallel trade more difficult, and that GSK had not put forward a sufficient case for exemption under Article 81(3).

For further information or advice please contact Franck Latrémolière.

Filed under Article 81, DG Competition, Healthcare, Pharmaceuticals.

Reckon LLP is an economics consultancy with expertise in data analysis, economic regulation and competition law.

About Reckon